Literature DB >> 24599317

β3-adrenergic receptor activity modulates melanoma cell proliferation and survival through nitric oxide signaling.

Massimo Dal Monte1, Irene Fornaciari, Grazie Paola Nicchia, Maria Svelto, Giovanni Casini, Paola Bagnoli.   

Abstract

We have recently shown in B16F10 melanoma cells that blockade of β3-adrenergic receptors (β3-ARs) reduces cell proliferation and induces apoptosis, likely through the involvement of nitric oxide (NO) signaling. Here, we tested the hypothesis that the effects of β3-AR blockade on melanoma cells are mainly mediated by a decrease in the activity of the NO pathway, possibly due to reduced expression of inducible NO synthase (iNOS). B16F10 cells were used. Nitrite production, iNOS expression, cell proliferation, and apoptosis were evaluated. β3-AR blockade with L-748,337 reduced basal nitrite production, while β3-AR stimulation with BRL37344 increased it. The effects of β3-AR blockade were prevented by NOS activation, while the effects of β3-AR activation were prevented by NOS inhibition. Treatments increasing nitrite production also increased iNOS expression, while treatments decreasing nitrite production reduced iNOS expression. Among the different NOS isoforms, experiments using L-748,337 or BRL37344 with activators or inhibitors targeting specific NOS isoforms demonstrated a prominent role of iNOS in nitrite production. β3-AR blockade decreased cell proliferation and induced apoptosis, while β3-AR activation had the opposite effects. The effects of β3-AR blockade/activation were prevented by iNOS activation/inhibition, respectively. Taken together, these results demonstrate that iNOS-produced NO is a downstream effector of β3-ARs and that the beneficial effects of β3-AR blockade on melanoma B16F10 cell proliferation and apoptosis are functionally linked to reduced iNOS expression and NO production. Although it is difficult to extrapolate these data to the clinical setting, the targeted inhibition of the β3-AR-NO axis may offer a new therapeutic perspective to treat melanomas.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24599317     DOI: 10.1007/s00210-014-0969-1

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  56 in total

1.  Inhibition of neuronal nitric oxide synthase activity by 3-[2-[4-(3-chloro-2-methylphenyl)- 1-piperazinyl]ethyl]-5, 6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate (DY-9760e), a novel neuroprotective agent, in vitro and in cultured neuroblastoma cells in situ.

Authors:  K Fukunaga; M Ohmitsu; E Miyamoto; T Sato; M Sugimura; T Uchida; Y Shirasaki
Journal:  Biochem Pharmacol       Date:  2000-09-01       Impact factor: 5.858

2.  Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner.

Authors:  Dimitri Lodygin; Antje Menssen; Heiko Hermeking
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

3.  Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in human malignant melanoma and their relation to angiogenesis.

Authors:  Y-T Tu; J Tao; Y-Q Liu; Y Li; C-Z Huang; X-B Zhang; Y Lin
Journal:  Clin Exp Dermatol       Date:  2006-05       Impact factor: 3.470

4.  Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.

Authors:  D Massi; A Franchi; I Sardi; L Magnelli; M Paglierani; L Borgognoni; U Maria Reali; M Santucci
Journal:  J Pathol       Date:  2001-06       Impact factor: 7.996

5.  A novel mechanism of coenzyme Q10 protects against human endothelial cells from oxidative stress-induced injury by modulating NO-related pathways.

Authors:  Kun-Ling Tsai; Yi-Hsiang Huang; Chung-Lan Kao; De-Ming Yang; Hsin-Chen Lee; Hsiang-Yun Chou; Yu-Chih Chen; Guang-Yuh Chiou; Li-Hsin Chen; Yi-Ping Yang; Tsan-Hung Chiu; Chiou-Sheng Tsai; Hsiu-Chung Ou; Shih-Hwa Chiou
Journal:  J Nutr Biochem       Date:  2011-06-17       Impact factor: 6.048

6.  Potent and selective human beta(3)-adrenergic receptor antagonists.

Authors:  M R Candelore; L Deng; L Tota; X M Guan; A Amend; Y Liu; R Newbold; M A Cascieri; A E Weber
Journal:  J Pharmacol Exp Ther       Date:  1999-08       Impact factor: 4.030

Review 7.  Nitric oxide signaling: classical, less classical, and nonclassical mechanisms.

Authors:  Antonio Martínez-Ruiz; Susana Cadenas; Santiago Lamas
Journal:  Free Radic Biol Med       Date:  2011-04-13       Impact factor: 7.376

8.  Functional properties of the rat and human beta 3-adrenergic receptors: differential agonist activation of recombinant receptors in Chinese hamster ovary cells.

Authors:  S B Liggett
Journal:  Mol Pharmacol       Date:  1992-10       Impact factor: 4.436

9.  Effect of β-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death.

Authors:  Vincenzo De Giorgi; Sara Gandini; Marta Grazzini; Silvia Benemei; Niccolò Marchionni; Pierangelo Geppetti
Journal:  Mayo Clin Proc       Date:  2013-11       Impact factor: 7.616

10.  Role of beta3-adrenergic receptors in the action of a tumour lipid mobilizing factor.

Authors:  S T Russell; K Hirai; M J Tisdale
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

View more
  17 in total

1.  Denominator changes may obscure results from single-well assays: β3-adrenoceptor ligand-induced changes of cell number as example.

Authors:  Katerina Okeke; Martina B Michel-Reher; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-05-04       Impact factor: 3.000

Review 2.  β-Adrenoceptors as drug targets in melanoma: novel preclinical evidence for a role of β3 -adrenoceptors.

Authors:  Massimo Dal Monte; Maura Calvani; Maurizio Cammalleri; Claudio Favre; Luca Filippi; Paola Bagnoli
Journal:  Br J Pharmacol       Date:  2018-12-18       Impact factor: 8.739

3.  Housing temperature-induced stress drives therapeutic resistance in murine tumour models through β2-adrenergic receptor activation.

Authors:  Jason W-L Eng; Chelsey B Reed; Kathleen M Kokolus; Rosemarie Pitoniak; Adam Utley; Mark J Bucsek; Wen Wee Ma; Elizabeth A Repasky; Bonnie L Hylander
Journal:  Nat Commun       Date:  2015-03-10       Impact factor: 14.919

Review 4.  β-Adrenergic modulation of cancer cell proliferation: available evidence and clinical perspectives.

Authors:  Marisa Coelho; Cátia Soares-Silva; Daniela Brandão; Franca Marino; Marco Cosentino; Laura Ribeiro
Journal:  J Cancer Res Clin Oncol       Date:  2016-10-05       Impact factor: 4.553

Review 5.  β-Blockade use for Traumatic Injuries and Immunomodulation: A Review of Proposed Mechanisms and Clinical Evidence.

Authors:  Tyler J Loftus; Philip A Efron; Lyle L Moldawer; Alicia M Mohr
Journal:  Shock       Date:  2016-10       Impact factor: 3.454

6.  β3 -Adrenoceptor as a potential immuno-suppressor agent in melanoma.

Authors:  Maura Calvani; Gennaro Bruno; Massimo Dal Monte; Romina Nassini; Filippo Fontani; Arianna Casini; Lorenzo Cavallini; Matteo Becatti; Francesca Bianchini; Francesco De Logu; Giulia Forni; Giancarlo la Marca; Lido Calorini; Paola Bagnoli; Paola Chiarugi; Alberto Pupi; Chiara Azzari; Pierangelo Geppetti; Claudio Favre; Luca Filippi
Journal:  Br J Pharmacol       Date:  2019-05-09       Impact factor: 8.739

7.  Norepinephrine promotes tumor microenvironment reactivity through β3-adrenoreceptors during melanoma progression.

Authors:  Maura Calvani; Floriane Pelon; Giuseppina Comito; Maria Letizia Taddei; Silvia Moretti; Stefania Innocenti; Romina Nassini; Gianni Gerlini; Lorenzo Borgognoni; Franco Bambi; Elisa Giannoni; Luca Filippi; Paola Chiarugi
Journal:  Oncotarget       Date:  2015-03-10

Review 8.  The Autonomic Regulation of Tumor Growth and the Missing Links.

Authors:  Maricris Bautista; Anand Krishnan
Journal:  Front Oncol       Date:  2020-05-13       Impact factor: 6.244

Review 9.  Neuroendocrine Factors in Melanoma Pathogenesis.

Authors:  Cristian Scheau; Carmen Draghici; Mihaela Adriana Ilie; Mihai Lupu; Iulia Solomon; Mircea Tampa; Simona Roxana Georgescu; Ana Caruntu; Carolina Constantin; Monica Neagu; Constantin Caruntu
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

Review 10.  Adrenergic Signaling: A Targetable Checkpoint Limiting Development of the Antitumor Immune Response.

Authors:  Guanxi Qiao; Minhui Chen; Mark J Bucsek; Elizabeth A Repasky; Bonnie L Hylander
Journal:  Front Immunol       Date:  2018-02-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.